Sosei Heptares’ Partner Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective Agonist TOKYO and CAMBRIDGE, United Kingdom, Oct….
Your Next Customer Isn’t Googling You. They’re Asking AI
Rhino Propels Federated AI into the Enterprise Tech Stack